Bristol-Myers Squibb Co.

+0.24 (+0.32%)
4:49:33 PM EDT: $76.26 +0.06 (+0.08%)
Products, Regulatory

U.S. Food And Drug Administration Approves Opdivo® (Nivolumab) For The Adjuvant Treatment Of Patients With High-Risk Urothelial Carcinoma

Published: 08/20/2021 16:06 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Adjuvant Treatment of Patients With High-risk Urothelial Carcinoma.
Bristol-myers Squibb - in Checkmate -274, Opdivo Nearly Doubled Median Disease-free Survival Compared to Placebo in Intent-to-treat Population.
Bristol-myers Squibb Co - Results Support Conversion of Opdivo's Accelerated Approval to a Regular Approval in This Setting.